Thermo Fisher Scientific said GAAP operating income margin and adjusted operating income margin decreased in 2024 due primarily to unfavorable business mix and strategic investments, partially offset by productivity improvements.

1. 01

   Thermo Fisher Scientific said GAAP operating income margin and adjusted operating income margin decreased in 2024 due primarily to unfavorable business mix and strategic investments, partially offset by productivity improvements.

2. 02

   The company said the acquisition of Olink Holding AB (publ) in 2024 used cash of $3.13 billion, and its investing activities also included net purchases of investments of $1.63 billion and purchases of property, plant and equipment of $1.40 billion.

3. 03

   Thermo Fisher Scientific said its financing activities in 2024 included the repurchase of $4.00 billion of the company's common stock (7.4 million shares) and the payment of $0.58 billion in cash dividends, while repayment of debt used cash of $3.61 billion.

4. 04

   The company said it expects its GAAP effective tax rate in 2025 will be between 9% and 11% and its adjusted tax rate will be approximately 11.5%.

Key figures

Fiscal year ended December 31, 2024

Revenue

$42.9B

Operating income

$7.3B

EPS

$16.53

Operating cash flow

$8.7B

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.